Dizhe Pharmaceuticals: Product Phase III Clinical Trial Achieves Positive Topline Results

MetaMuskRat · 2026-03-22T10:10:48+00:00

Dizhe Pharmaceuticals announced that its研发的舒沃哲®在针对EGFR 20号外显子插入突变的晚期非小细胞肺癌的Ⅲ期临床研究中取得阳性结果，成为全球首个在此领域获得成功的口服靶向药物。

MetaMuskRat

2026-03-22 10:10:48

Abstract generation in progress

People’s Financial News, March 22 — DIZHE Medicine (688192) announced on March 22 that its self-developed product, ZEGFROVY® (generic name: Shuvo Tini Tablets), has achieved the primary endpoint and positive topline results in the international multicenter Phase III clinical trial “Wu-Kong 28” (WU-KONG28) for first-line treatment of epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins) in advanced non-small cell lung cancer (NSCLC). This is the world’s first and only oral targeted drug to achieve positive results in an international multicenter randomized Phase III clinical trial for first-line treatment of EGFR exon20ins NSCLC.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes